Evaluating Clinical Efficacy and Survival Outcomes of Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.

Cureus · 2026 · PMC12964323 · PMID 41797880

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significancep = 0.18not close (p > 0.1)

When compared with chemotherapy, pooled meta-analysis demonstrated a numerical survival advantage for crizotinib; however, this difference did not reach statistical significance (OR = 1.56; 95% CI, 0.81-2.99; p = 0.18) (Figure 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.